This bill would amend the Federal Food, Drug, and Cosmetic Act to clarify the regulatory rules that decide when a product is treated as a drug rather than a dietary supplement. Its stated goals are to encourage innovation and to increase and protect consumer access to dietary supplements. The bill was introduced by Representative Diana Harshbarger and has been referred to the House Committee on Energy and Commerce. No publicly available information about specific text or detailed provisions.
The bill's title says it seeks clearer rules about "drug preclusion" for dietary supplements. That means lawmakers want to make clearer when a product is regulated as a drug instead of a supplement. No publicly available information explains how the bill would change approvals, labeling, or how quickly new supplements reach the market.
No publicly available information on costs, budget effects, or federal spending related to this bill.
The bill's stated aim is to encourage innovation in dietary supplements and to increase and protect consumer access by clarifying the regulatory framework that governs when a product is considered a drug.
No publicly available information on objections, opposition views, or possible concerns about the bill.